​
​

Eli Lilly and Company (LLY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

LLY Stock Forecast

Eli Lilly and Company stock forecast is as follows: an average price target of $778.10 (represents a 4.27% upside from LLY’s last price of $746.20) and a rating consensus of 'Buy', based on 21 wall street analysts offering a 1-year stock forecast.

LLY Price Target

The average price target for Eli Lilly and Company (LLY) is $778.10 based on 1-year price targets from 21 Wall Street analysts in the past 3 months, with a price target range of $1.15K to $300.00. This represents a potential 4.27% upside from LLY's last price of $746.20.

LLY Analyst Ratings

Buy

According to 21 Wall Street analysts, Eli Lilly and Company's rating consensus is 'Buy'. The analyst rating breakdown for LLY stock is 0 'Strong Buy' (0.00%), 21 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Eli Lilly and Company Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 31, 2024Evan David SeigermanBMO Capital$1.01K$829.7421.72%35.35%
Oct 14, 2024Andrew BerensLeerink Partners$990.00$932.066.22%32.67%
Sep 13, 2024Peter VerdultCitigroup$1.06K$935.0213.37%42.05%
Aug 27, 2024Terence FlynnMorgan Stanley$1.11K$957.5115.51%48.22%
Aug 14, 2024Kerry HolfordBerenberg Bank$1.05K$908.0515.63%40.71%
Aug 12, 2024James ShinDeutsche Bank$1.02K$891.6814.95%37.36%
Aug 09, 2024Chris ShibutaniGoldman Sachs$856.00$891.68-4.00%14.71%
Aug 09, 2024Mohit BansalWells Fargo$1.00K$845.3118.30%34.01%
Aug 09, 2024Evan David SeigermanBMO Capital$1.10K$845.3130.25%47.55%
Aug 09, 2024Geoff MeachamBank of America Securities$1.15K$845.3136.04%54.11%
Row per page
Go to

The latest Eli Lilly and Company stock forecast, released on Oct 31, 2024 by Evan David Seigerman from BMO Capital, set a price target of $1.01K, which represents a 21.72% increase from the stock price at the time of the forecast ($829.74), and a 35.35% increase from LLY last price ($746.20).

Eli Lilly and Company Price Target by Period

1M3M12M
# Anlaysts1426
Avg Price Target$1.01K$1.04K$949.04
Last Closing Price$746.20$746.20$746.20
Upside/Downside35.35%39.57%27.18%

In the current month, the average price target of Eli Lilly and Company stock is $1.01K, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 35.35% increase as opposed to Eli Lilly and Company's last price of $746.20. This month's average price target is down -3.02% compared to last quarter, and up 6.42% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 17, 2024Bernstein-OutperformInitialise
Oct 14, 2024Leerink PartnersOutperformOutperformHold
Oct 03, 2024Wells FargoBuyBuyHold
Oct 03, 2024Raymond JamesUnderperformUnderperformHold
Sep 25, 2024Goldman SachsBuyBuyHold
Sep 20, 2024Deutsche BankBuyBuyHold
Sep 13, 2024BMO CapitalOutperformOutperformHold
Sep 09, 2024Wells FargoBuyBuyHold
Sep 09, 2024JefferiesUnderperformUnderperformHold
Aug 27, 2024Deutsche BankBuyBuyHold
Row per page
Go to

Eli Lilly and Company's last stock rating was published by Bernstein on Oct 17, 2024. The company Initialise its LLY rating from "null" to "Outperform".

Eli Lilly and Company Financial Forecast

Eli Lilly and Company Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue-----------$6.96B$7.30B$6.94B$6.49B$7.81B$8.00B$6.77B$6.74B$6.81B$7.44B$5.74B$5.50B$5.86B$6.11B$5.48B$5.64B$5.09B$5.70B$5.23B
Avg Forecast$15.32B$14.57B$14.05B$13.47B$14.00B$12.10B$9.98B$8.94B$8.95B$8.97B$7.58B$6.86B$7.33B$6.89B$6.85B$7.29B$7.69B$6.64B$6.60B$6.93B$7.27B$5.88B$5.76B$5.49B$5.91B$5.50B$5.58B$5.20B$4.19B$5.12B
High Forecast$15.53B$14.77B$14.24B$13.65B$14.30B$12.14B$9.99B$8.94B$9.20B$9.53B$7.69B$6.96B$7.43B$6.89B$6.85B$7.29B$7.69B$6.64B$6.60B$6.93B$7.27B$5.88B$5.76B$5.49B$5.91B$5.50B$5.58B$5.20B$5.02B$6.15B
Low Forecast$14.97B$14.24B$13.73B$13.16B$13.66B$12.05B$9.98B$8.94B$8.73B$8.29B$7.41B$6.71B$7.17B$6.89B$6.85B$7.29B$7.69B$6.64B$6.60B$6.93B$7.27B$5.88B$5.76B$5.49B$5.91B$5.50B$5.58B$5.20B$3.35B$4.10B
# Analysts1111126347136655511121110993332234710
Surprise %-----------1.01%1.00%1.01%0.95%1.07%1.04%1.02%1.02%0.98%1.02%0.98%0.95%1.07%1.03%1.00%1.01%0.98%1.36%1.02%

Eli Lilly and Company's average Quarter revenue forecast for Jun 23 based on 6 analysts is $7.58B, with a low forecast of $7.41B, and a high forecast of $7.69B. LLY's average Quarter revenue forecast represents a 8.95% increase compared to the company's last Quarter revenue of $6.96B (Mar 23).

Eli Lilly and Company EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1111126347136655511121110993332234710
EBITDA---------$-6.07B$-6.09B$1.70B$2.39B$2.40B$2.08B$2.74B$2.37B$1.71B$2.05B$1.91B$2.93B$1.89B$2.06B$2.05B$2.10B$1.80B$1.82B$4.85B$1.93B$494.70M
Avg Forecast$4.63B$4.40B$4.24B$4.07B$4.23B$3.66B$3.02B$2.08B$2.70B$2.71B$2.29B$1.89B$2.57B$2.22B$2.21B$1.72B$2.48B$2.14B$2.13B$2.15B$2.34B$1.89B$1.86B$1.67B$1.91B$1.77B$1.80B$4.78B$1.57B$484.39M
High Forecast$4.69B$4.46B$4.30B$4.12B$4.32B$3.67B$3.02B$2.50B$2.78B$2.88B$2.32B$2.27B$3.09B$2.22B$2.21B$2.06B$2.48B$2.14B$2.13B$2.58B$2.34B$1.89B$1.86B$2.01B$1.91B$1.77B$1.80B$5.74B$1.88B$581.27M
Low Forecast$4.52B$4.30B$4.15B$3.98B$4.13B$3.64B$3.01B$1.67B$2.64B$2.50B$2.24B$1.51B$2.06B$2.22B$2.21B$1.38B$2.48B$2.14B$2.13B$1.72B$2.34B$1.89B$1.86B$1.34B$1.91B$1.77B$1.80B$3.82B$1.25B$387.51M
Surprise %----------2.24%-2.66%0.90%0.93%1.08%0.94%1.59%0.96%0.80%0.96%0.89%1.25%1.00%1.11%1.22%1.10%1.02%1.01%1.02%1.23%1.02%

6 analysts predict LLY's average Quarter EBITDA for Jun 23 to be $2.29B, with a high of $2.32B and a low of $2.24B. This is 34.46% upper than Eli Lilly and Company's previous annual EBITDA (Mar 23) of $1.70B.

Eli Lilly and Company Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1111126347136655511121110993332234710
Net Income---------$-57.40M$1.76B$1.34B$1.94B$1.45B$952.50M$1.90B$1.73B$1.11B$1.39B$1.36B$2.12B$1.21B$1.41B$1.46B$1.50B$1.25B$1.33B$4.24B$1.22B$-110.80M
Avg Forecast$4.03B$5.38B$5.08B$4.66B$4.95B$1.29B$2.48B$2.00B$2.08B$-161.94M$1.79B$1.82B$1.88B$1.73B$1.54B$1.66B$2.21B$1.77B$1.71B$1.52B$2.14B$1.55B$1.41B$1.19B$1.38B$1.27B$1.31B$4.18B$991.16M$-108.49M
High Forecast$4.10B$5.48B$5.17B$4.74B$5.05B$1.34B$2.48B$2.41B$2.35B$377.86M$1.82B$2.19B$2.25B$1.73B$1.54B$1.99B$2.21B$1.77B$1.71B$1.82B$2.14B$1.55B$1.41B$1.43B$1.38B$1.27B$1.31B$5.01B$1.19B$-86.79M
Low Forecast$3.91B$5.22B$4.93B$4.52B$4.83B$1.23B$2.48B$1.60B$1.80B$-971.64M$1.74B$1.46B$1.50B$1.73B$1.54B$1.33B$2.21B$1.77B$1.71B$1.22B$2.14B$1.55B$1.41B$952.63M$1.38B$1.27B$1.31B$3.34B$792.93M$-130.19M
Surprise %---------0.35%0.98%0.74%1.03%0.84%0.62%1.15%0.78%0.63%0.81%0.89%0.99%0.78%1.00%1.22%1.09%0.99%1.01%1.02%1.23%1.02%

Eli Lilly and Company's average Quarter net income forecast for Sep 23 is $-161.94M, with a range of $-971.64M to $377.86M. LLY's average Quarter net income forecast represents a -109.18% decrease compared to the company's last Quarter net income of $1.76B (Jun 23).

Eli Lilly and Company SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1111126347136655511121110993332234710
SG&A---------$1.80B$1.93B$1.75B$1.64B$1.61B$1.63B$1.56B$1.59B$1.58B$1.69B$1.58B$1.55B$1.57B$2.90B$1.55B$1.70B$1.41B$1.59B$1.52B$1.50B$1.54B
Avg Forecast$3.63B$3.45B$3.33B$3.19B$3.32B$2.86B$2.36B$1.64B$2.12B$2.12B$1.80B$1.49B$1.73B$1.65B$1.64B$1.36B$1.84B$1.59B$1.58B$1.77B$1.74B$1.41B$1.38B$1.27B$1.42B$1.32B$1.34B$1.49B$1.22B$1.51B
High Forecast$3.68B$3.50B$3.37B$3.23B$3.39B$2.88B$2.37B$1.97B$2.18B$2.26B$1.82B$1.79B$2.08B$1.65B$1.64B$1.63B$1.84B$1.59B$1.58B$2.12B$1.74B$1.41B$1.38B$1.52B$1.42B$1.32B$1.34B$1.79B$1.47B$1.82B
Low Forecast$3.55B$3.37B$3.25B$3.12B$3.23B$2.85B$2.36B$1.31B$2.07B$1.96B$1.76B$1.19B$1.38B$1.65B$1.64B$1.09B$1.84B$1.59B$1.58B$1.41B$1.74B$1.41B$1.38B$1.01B$1.42B$1.32B$1.34B$1.20B$976.99M$1.21B
Surprise %---------0.85%1.07%1.17%0.95%0.98%0.99%1.15%0.86%0.99%1.07%0.89%0.89%1.12%2.10%1.22%1.20%1.07%1.19%1.02%1.23%1.02%

Eli Lilly and Company's average Quarter SG&A projection for Dec 23 is $2.12B, based on 7 Wall Street analysts, with a range of $2.07B to $2.18B. The forecast indicates a 17.44% rise compared to LLY last annual SG&A of $1.80B (Sep 23).

Eli Lilly and Company EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1111126347136655511121110993332234710
EPS---------$-0.06$1.96$1.49$2.04$1.61$1.06$2.11$1.81$1.16$1.53$1.41$2.21$1.26$1.48$1.52$1.56$1.31$1.37$4.33$1.16$-0.10
Avg Forecast$4.45$5.95$5.62$5.15$5.47$1.42$2.74$2.47$2.30$-0.18$1.98$1.73$1.78$1.91$1.70$2.29$2.45$1.96$1.89$2.12$2.37$1.71$1.56$1.48$1.52$1.40$1.45$1.31$0.92$0.94
High Forecast$4.53$6.05$5.71$5.24$5.58$1.48$2.74$2.47$2.59$0.42$2.01$1.76$1.87$1.91$1.70$2.29$2.45$1.96$1.89$2.12$2.37$1.71$1.56$1.48$1.52$1.40$1.45$1.31$1.10$1.13
Low Forecast$4.32$5.77$5.45$5.00$5.33$1.36$2.74$2.46$1.99$-1.07$1.92$1.68$1.70$1.91$1.70$2.29$2.45$1.96$1.89$2.12$2.37$1.71$1.56$1.48$1.52$1.40$1.45$1.31$0.74$0.75
Surprise %---------0.36%0.99%0.86%1.14%0.84%0.62%0.92%0.74%0.59%0.81%0.67%0.93%0.74%0.95%1.03%1.03%0.93%0.95%3.31%1.26%-0.11%

According to 13 Wall Street analysts, Eli Lilly and Company's projected average Quarter EPS for Sep 23 is $-0.18, with a low estimate of $-1.07 and a high estimate of $0.42. This represents a -109.13% decrease compared to LLY previous annual EPS of $1.96 (Jun 23).

Eli Lilly and Company Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PFEPfizer$24.80$44.7680.48%Hold
MRKMerck$96.31$128.8933.83%Buy
BMYBristol-Myers Squibb Company$56.22$65.5016.51%Hold
JNJJohnson & Johnson$154.00$179.1316.32%Buy
AMGNAmgen$283.61$301.816.42%Buy
ABBVAbbVie$164.99$173.305.04%Buy
LLYEli Lilly and Company$746.20$778.104.27%Buy
GILDGilead Sciences$88.40$81.77-7.50%Buy

LLY Forecast FAQ

Is Eli Lilly and Company a good buy?

Yes, according to 21 Wall Street analysts, Eli Lilly and Company (LLY) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 21 'Buy' recommendations, accounting for 100.00% of LLY's total ratings.

What is LLY's price target?

Eli Lilly and Company (LLY) average price target is $778.1 with a range of $300 to $1.15K, implying a 4.27% from its last price of $746.2. The data is based on 21 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Eli Lilly and Company stock go up soon?

According to Wall Street analysts' prediction for LLY stock, the company can go up by 4.27% (from the last price of $746.2 to the average price target of $778.1), up by 54.11% based on the highest stock price target, and down by -59.80% based on the lowest stock price target.

Can Eli Lilly and Company stock reach $1.1K?

LLY's highest twelve months analyst stock price target of $1.15K supports the claim that Eli Lilly and Company can reach $1.1K in the near future.

What is Eli Lilly and Company's current price target trend?

1 Wall Street analyst forecast a $1.01K price target for Eli Lilly and Company (LLY) this month, up 35.35% from its last price of $746.2. Compared to the last 3 and 12 months, the average price target increased by 39.57% and increased by 27.18%, respectively.

What are Eli Lilly and Company's analysts' financial forecasts?

Eli Lilly and Company's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $45.02B (high $45.37B, low $44.62B), average EBITDA is $12.99B (high $13.51B, low $12.45B), average net income is $10.73B (high $11.28B, low $10.14B), average SG&A $10.19B (high $10.6B, low $9.76B), and average EPS is $12.1 (high $12.27, low $11.9). LLY's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $57.41B (high $58.19B, low $56.11B), average EBITDA is $17.35B (high $17.58B, low $16.96B), average net income is $19.15B (high $19.49B, low $18.59B), average SG&A $13.59B (high $13.78B, low $13.29B), and average EPS is $21.16 (high $21.54, low $20.54).

Did the LLY's actual financial results beat the analysts' financial forecasts?

Based on Eli Lilly and Company's last annual report (Dec 2022), the company's revenue was $28.54B, beating the average analysts forecast of $28.36B by 0.65%. Apple's EBITDA was $9.43B, beating the average prediction of $8.72B by 8.19%. The company's net income was $6.24B, missing the average estimation of $6.8B by -8.17%. Apple's SG&A was $6.44B, beating the average forecast of $6.38B by 1.00%. Lastly, the company's EPS was $6.93, missing the average prediction of $7.69 by -9.88%. In terms of the last quarterly report (Mar 2023), Eli Lilly and Company's revenue was $6.96B, beating the average analysts' forecast of $6.86B by 1.41%. The company's EBITDA was $1.7B, missing the average prediction of $1.89B by -9.95%. Eli Lilly and Company's net income was $1.34B, missing the average estimation of $1.82B by -26.21%. The company's SG&A was $1.75B, beating the average forecast of $1.49B by 17.23%. Lastly, the company's EPS was $1.49, missing the average prediction of $1.73 by -13.66%